Healthcare of Ontario Pension Plan Trust Fund Has $2.79 Million Stake in 2seventy bio, Inc. (NASDAQ:TSVT)

Healthcare of Ontario Pension Plan Trust Fund lowered its stake in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 59.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 590,000 shares of the company's stock after selling 878,500 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned approximately 1.15% of 2seventy bio worth $2,785,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of TSVT. Price T Rowe Associates Inc. MD raised its position in shares of 2seventy bio by 11.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 28,929 shares of the company's stock worth $155,000 after purchasing an additional 2,893 shares during the period. Public Employees Retirement System of Ohio raised its holdings in 2seventy bio by 2,637.0% during the 1st quarter. Public Employees Retirement System of Ohio now owns 27,370 shares of the company's stock worth $146,000 after buying an additional 26,370 shares during the period. Nisa Investment Advisors LLC acquired a new stake in 2seventy bio during the 2nd quarter worth about $52,000. Bank of New York Mellon Corp lifted its stake in 2seventy bio by 5.4% during the second quarter. Bank of New York Mellon Corp now owns 196,959 shares of the company's stock valued at $758,000 after buying an additional 10,077 shares in the last quarter. Finally, BBR Partners LLC boosted its holdings in shares of 2seventy bio by 66.7% in the second quarter. BBR Partners LLC now owns 25,000 shares of the company's stock worth $96,000 after buying an additional 10,000 shares during the period. Institutional investors and hedge funds own 93.90% of the company's stock.

2seventy bio Stock Up 0.8 %

Shares of TSVT stock traded up $0.03 during trading hours on Friday, reaching $3.99. 92,979 shares of the stock traded hands, compared to its average volume of 353,325. The firm has a market capitalization of $205.84 million, a PE ratio of -2.15 and a beta of 1.78. 2seventy bio, Inc. has a 1-year low of $1.67 and a 1-year high of $6.40. The business has a fifty day moving average price of $4.49 and a 200 day moving average price of $4.42.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.